These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 22161825)
1. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Eccles SA Int J Dev Biol; 2011; 55(7-9):685-96. PubMed ID: 22161825 [TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Roskoski R Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458 [TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. Steelman LS; Chappell WH; Akula SM; Abrams SL; Cocco L; Manzoli L; Ratti S; Martelli AM; Montalto G; Cervello M; Libra M; Candido S; McCubrey JA Adv Biol Regul; 2020 Dec; 78():100758. PubMed ID: 33022466 [TBL] [Abstract][Full Text] [Related]
6. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion. Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194 [TBL] [Abstract][Full Text] [Related]
7. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853 [TBL] [Abstract][Full Text] [Related]
8. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640 [TBL] [Abstract][Full Text] [Related]
10. [Erb-2 overexpression in breast cancer]. Swiatoniowski G; Dabrowska M; Kłaniewski T; Molenda W Ginekol Pol; 2003 Apr; 74(4):332-8. PubMed ID: 12916278 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552 [TBL] [Abstract][Full Text] [Related]
12. Biology of HER2 and its importance in breast cancer. Yarden Y Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor activity is necessary for mouse basal cell proliferation. Brechbuhl HM; Li B; Smith RW; Reynolds SD Am J Physiol Lung Cell Mol Physiol; 2014 Nov; 307(10):L800-10. PubMed ID: 25217659 [TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Stern DF Breast Cancer Res; 2000; 2(3):176-83. PubMed ID: 11250707 [TBL] [Abstract][Full Text] [Related]
16. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079 [TBL] [Abstract][Full Text] [Related]
17. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Singleton KR; Kim J; Hinz TK; Marek LA; Casás-Selves M; Hatheway C; Tan AC; DeGregori J; Heasley LE Mol Pharmacol; 2013 Apr; 83(4):882-93. PubMed ID: 23371912 [TBL] [Abstract][Full Text] [Related]
18. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769 [TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324 [TBL] [Abstract][Full Text] [Related]
20. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Bedard PL; de Azambuja E; Cardoso F Curr Cancer Drug Targets; 2009 Mar; 9(2):148-62. PubMed ID: 19275756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]